Yazhen Qin, Jin Lu, L. Bao, Honghu Zhu, Jin-lan Li, Ling-di Li, Y. Lai, Hong-xia Shi, Ya-zhe Wang, Yan-rong Liu, B. Jiang, Xiaojun Huang
{"title":"硼替佐米提高过表达黑色素瘤优先表达抗原的多发性骨髓瘤患者的无进展生存率","authors":"Yazhen Qin, Jin Lu, L. Bao, Honghu Zhu, Jin-lan Li, Ling-di Li, Y. Lai, Hong-xia Shi, Ya-zhe Wang, Yan-rong Liu, B. Jiang, Xiaojun Huang","doi":"10.3760/cma.j.issn.0366-6999.20132356","DOIUrl":null,"url":null,"abstract":"Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study. Methods The transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real‐time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+). Results Sixty‐two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression‐free survival (PFS, n=96, all P >0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two‐year PFS rate in patients treated with non‐bortezomib‐containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two‐year PFS rate in patients with bortezomib‐containing regimens (77.5% vs. 63.9%, P >0.05). When the patients were categorized into PRAME (+) and PRAME (‐) groups, treatment with bortezomib‐containing regimens predicted a higher two‐year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two‐year PFS rate in PRAME (‐) patients (63.9% vs. 76.9%, P >0.05). Conclusion PRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non‐bortezomib‐containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5000,"publicationDate":"2014-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Bortezomib improves progression‐free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma\",\"authors\":\"Yazhen Qin, Jin Lu, L. Bao, Honghu Zhu, Jin-lan Li, Ling-di Li, Y. Lai, Hong-xia Shi, Ya-zhe Wang, Yan-rong Liu, B. Jiang, Xiaojun Huang\",\"doi\":\"10.3760/cma.j.issn.0366-6999.20132356\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study. Methods The transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real‐time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+). Results Sixty‐two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression‐free survival (PFS, n=96, all P >0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two‐year PFS rate in patients treated with non‐bortezomib‐containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two‐year PFS rate in patients with bortezomib‐containing regimens (77.5% vs. 63.9%, P >0.05). When the patients were categorized into PRAME (+) and PRAME (‐) groups, treatment with bortezomib‐containing regimens predicted a higher two‐year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two‐year PFS rate in PRAME (‐) patients (63.9% vs. 76.9%, P >0.05). Conclusion PRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non‐bortezomib‐containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.\",\"PeriodicalId\":10183,\"journal\":{\"name\":\"Chinese Medical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2014-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Medical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.issn.0366-6999.20132356\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.issn.0366-6999.20132356","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 11
摘要
背景:人们已经做出了重大努力,以确定使用新型疗法(如硼替佐米治疗多发性骨髓瘤)治疗患者的差异因素。黑色素瘤癌/睾丸抗原优先表达抗原(PRAME)在MM中的确切表达模式和预后价值尚不清楚,本研究对此进行了探讨。方法采用实时定量聚合酶链反应检测100例新诊断MM患者骨髓标本中PRAME的转录水平,并通过回顾性生存分析确定PRAME的预后价值。PRAME表达高于正常骨髓上限定义为PRAME过表达或PRAME(+)。结果62例(62.0%)患者PRAME过表达。PRAME过表达对患者的总生存期(n=100)或无进展生存期(PFS, n=96,均P < 0.05)均无预后意义。患者也根据是否使用硼替佐米的方案进行分类。在接受非硼替佐米方案治疗的患者中,PRAME过表达倾向于与较低的两年PFS率相关(53.5%对76.9%,P=0.071)。相比之下,它与含硼替佐米方案患者的两年PFS率无关(77.5%对63.9%,P < 0.05)。当患者被分为PRAME(+)组和PRAME(‐)组时,含硼替佐米治疗方案预测PRAME(+)患者的2年PFS率较高(77.5% vs. 53.5%, P=0.027),但对PRAME(‐)患者的2年PFS率无显著影响(63.9% vs. 76.9%, P= 0.05)。结论PRAME过表达可能是不含硼替佐米方案治疗MM患者PFS的不良预后因素。硼替佐米改善过表达PRAME患者的PFS。
Bortezomib improves progression‐free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study. Methods The transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real‐time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+). Results Sixty‐two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression‐free survival (PFS, n=96, all P >0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two‐year PFS rate in patients treated with non‐bortezomib‐containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two‐year PFS rate in patients with bortezomib‐containing regimens (77.5% vs. 63.9%, P >0.05). When the patients were categorized into PRAME (+) and PRAME (‐) groups, treatment with bortezomib‐containing regimens predicted a higher two‐year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two‐year PFS rate in PRAME (‐) patients (63.9% vs. 76.9%, P >0.05). Conclusion PRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non‐bortezomib‐containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.
期刊介绍:
The Chinese Medical Journal (CMJ) is published semimonthly in English by the Chinese Medical Association, and is a peer reviewed general medical journal for all doctors, researchers, and health workers regardless of their medical specialty or type of employment. Established in 1887, it is the oldest medical periodical in China and is distributed worldwide. The journal functions as a window into China’s medical sciences and reflects the advances and progress in China’s medical sciences and technology. It serves the objective of international academic exchange. The journal includes Original Articles, Editorial, Review Articles, Medical Progress, Brief Reports, Case Reports, Viewpoint, Clinical Exchange, Letter,and News,etc. CMJ is abstracted or indexed in many databases including Biological Abstracts, Chemical Abstracts, Index Medicus/Medline, Science Citation Index (SCI), Current Contents, Cancerlit, Health Plan & Administration, Embase, Social Scisearch, Aidsline, Toxline, Biocommercial Abstracts, Arts and Humanities Search, Nuclear Science Abstracts, Water Resources Abstracts, Cab Abstracts, Occupation Safety & Health, etc. In 2007, the impact factor of the journal by SCI is 0.636, and the total citation is 2315.